Arkolith/Insider Trading/GTHX/Form 4

Umstead John W. V

Chief Financial OfficerG1 Therapeutics, Inc. (GTHX) · full profile →Form 4 · filed Sep 18, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 18, 2024Disposed to issuer(D)168K——19K
Sep 18, 2024Tender(U)19K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 18, 2024Disposed to issuer(D)100K——0
Sep 18, 2024Disposed to issuer(D)75K——0
Sep 18, 2024Disposed to issuer(D)6K——0

Transaction Codes

D
Disposition to the issuer
U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-107791) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML